Ezetimibe Dosing for High Cholesterol

Efficacy and LDL-C Reduction

• The American College of Cardiology reports that when combined with statin therapy, ezetimibe provides an additional 17-18% placebo-corrected incremental reduction in LDL-C 1, 2
• The combination of ezetimibe with bempedoic acid can achieve a 38% reduction in LDL-C when added to statin therapy 3

Drug Interactions

• The American College of Cardiology recommends avoiding concomitant use of ezetimibe with simvastatin >20 mg daily or pravastatin >40 mg daily due to potential drug interactions 2, 4
• The American College of Cardiology suggests monitoring for interactions with cyclosporine and fibrates 4

Clinical Use in Treatment Algorithms

• The American College of Cardiology recommends ezetimibe as the initial non-statin agent for most patients when additional LDL-C lowering is desired beyond statin therapy 4, 5
• The American College of Cardiology prefers ezetimibe as the initial non-statin therapy due to its tolerability, convenience, and single-tablet daily dose 4

Safety Profile

• The American College of Cardiology notes that common adverse effects of ezetimibe include upper respiratory tract infection, muscle spasms, back pain, and abdominal pain 2
• The American College of Cardiology advises discontinuing ezetimibe when pregnancy is recognized unless benefits outweigh potential risks 2